CCZ1B vacuolar protein trafficking and biogenesis associatedGenealiases: C7orf28B · H_NH0577018.2
Q-omics provides the consensus-scored CCZ1B profile across patient tissues and cancer cell-line models. CCZ1B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CCZ1B is differentially expressed in 16, with the highest sampling consensus in KIRP. Additionally, CCZ1B RNA expression shows 18,038 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KIRP, and UVM as cancer lineages where CCZ1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCZ1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCZ1B survival associations across molecular data types. CCZ1B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCZ1B RNA expression–survival associations across cancer types. High CCZ1B expression shows unfavorable associations in LIHC, LGG, MESO, HNSC, KIRC and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CCZ1B RNA expression.
This table summarizes CCZ1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCZ1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCZ1B shows higher tumor expression in KIRP, LUAD, KIRC, BLCA, LIHC and HNSC. The KIRP box plot shows higher CCZ1B RNA expression in tumor versus normal tissue (log2 FC = +1.012, t-test p < 0.001).
This table shows molecular features associated with CCZ1B in patient tissues and cancer cell lines. In patient samples, CCZ1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCZ1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
